Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC)
Literature
Read More
STAG2-mutated AML patients: ASXL1 cohesin binding motif status and mutation landscape
Literature
Read More
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirst®-Lung Liquid Biopsy Test
Press Release
Read More
NeoGenomics To Virtually Participate In 17th Annual Craig-Hallum Institutional Investor Conference
Press Release
Read More
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Literature
Read More
NeoGenomics To Virtually Participate In Fireside Chat At BofA Securities 2020 Health Care Conference
Press Release
Read More